I remember being excited about the ability to treat strokes if a drug was administered within four hours of an event. Now it looks like it may soon expand to over a full day:
“Cleveland-based Athersys, with a market value of about $200 million, demonstrated evidence in a midstage trial that its therapy may be able to expand the emergency treatment window for major strokes to up to 36 hours, compared with about four hours with current drugs, potentially allowing many more patients to avoid crippling disabilities.”
See here for more details.
I decided to type this up before the University of Colordo / Chromadex study is out at the end of this year or early next year when we will learn more about what the vitamin B3 supplement NR can do for us humans at 500 mg and 1000 mg, while the Elysium study showed effects of 250 mg and 500 mg although included pterostilbine as well.
I started to take 125 mg of NR last November at the age of 48 and soon noticed a change with sleep. Within a day or two, I felt my sleep was deeper and had vivid dreams as I had more often when younger. When I woke up, I was wide awake as well. Overall, I liked the changes, but it took a while to get used to.
From January, I began taking 250 mg of NR a day in the morning.
After six months, I got a haircut in April and when I rubbed my hand through my hair I could tell something was different: my hair was much thicker everywhere – in the back, on the sides and on top. I didn’t expect hair growth at all. I asked a 60 year old friend if he could tell that my hair was thicker, and he laughed: “It’s obvious!” His mostly gray/white hair had developed black streaks that became more pronounced after he took 250 mg of NR after six months and more so today at his one year mark. (He also thinks his nearsightdness has improved to when he was 40, but he hasn’t formally tested this yet with an optometrist.)
The Elysium study just published showed an almost 8% increase in the average distance walked in 6 minutes for healthy 60 to 80 year olds at 500 mg a day for 8 weeks but no increase at 250 mg. Likewise, there was a 7 to 8% average increase with a chair balance test at 500 mg but no impovement at 250 mg.
I expect to read about positive results with just 250 mg of NR a day but can also see that this might be marketed as a 375 mg and 500 mg supplement as well. Keep in mind that an obese person may find increased endurance at 250 mg as well since there metobolism is probably further from normal compared with non-obese people.
Bring on the U of Colorado results where cognitive function was measured as well!
Looks like potetnial good news for heart failure patients
IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research by Dr. Mathias Mericksay and colleagues at the l’Université Paris-Sud, and Dr. Charles Brenner and colleagues at the University of Iowa, published in the journal Circulation. This research revealed that in a mouse model of heart failure, a loss of NAD levels is accompanied by activation of the nicotinamide riboside (NR) kinase pathway; administration of NIAGEN® in this model stabilizes NAD levels and leads to protective effects on cardiac function that may someday lead to a new therapeutic option for heart failure patients.
….In this new research, Drs. Mericksay, Brenner and colleagues discovered that in heart failure, activation of the NR kinase pathway, which occurs as a result of energy stress and NAD depletion is common to humans and mice. Because of activation of the NR kinase pathway, NR restores but nicotinamide fails to restore NAD levels. Measures of cardiac function are improved with oral administration of NR in this mouse model of heart failure.
Because the depression in NAD and the activation of the NR kinase pathway are common between humans and mice, the research strongly suggests that NIAGEN® may be capable of protecting against human heart failure….
Nature just published the results of the Elysium NR+pterostilbine study of 120 healthy 60 to 80 year olds with BMIs under 30.
1) 250 mg of NR and 50 mg of pterostilbine raised NAD+ levels by 40% for eight weeks in healthy 60 to 80 year olds. 500 mg of NR and 100 mg of pterostilbine raised NAD+ levels up to 90% after four weeks but steadily lowered to 55%. (The last part is new.)
2) Liver test: ASL went down while AST decreased but not with statsitical significance. A new trial is focusing on liver health.
3) There were very slight or no changes in heart rate, blood pressure, glucose levels or triglyceryde levels for both groups.
4) “Significantly” improved mobility with a 30 second chair-stand test and a 6 minute walk test for the 500 mg but *not* the 250 mg group. Unfortunately, the extent of the physical gains was not reported.
Next up: Elysium is focusing on liver health, brain health, cardiovascular, muscular disorders and diabetes in new separate studies. The U of Colorado study is also expected to be published in a few weeks.
ChromaDex announced yesterday at an earnings report call that the long awaited University of Colorado human study of NR will be published very “soon.” We don’t know if “soon” means sometime before the Tokyo Summer Olympics or within a few weeks.
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults studied the effects of taking 250 mg, 500 mg, and 1000 mg of NR on liver enzymes and kidney function along with artery flow dilation, aortic pulse wave velocity, cognitive and motor function. 30 people participated in the 6-week trial last fall and the results were discussed in a closed forum this past summer.
I read a couple of days ago that ChromaDex has recently sued Elysium for $200 million dollars as Dave reminded in the comments section. I didn’t intend to post much on the lawsuits until more seemed clearer, possibly from early next year.
According to the Right to Assembly blog:
The plan, according to ChromaDex’s complaint, ran something like this: The goal was to acquire ChromaDex. So Elysium,
1. Negotiated an exclusivity arrangement that limited ChromaDex’s ability to sell to other customers
2. Stole two key ChromaDex employees
3. Placed a $3M order that it did not intend to pay for, and
4. Disseminated false information to investors
I don’t think ChromaDex has a good chance of winning $200 million as it tries to show each of the above points. This will depend in great part if Elysium is found violating ChromaDex’s patents on the manufacturing process of NR. I assume this lawsuit is also an attempt of at least winning a much lower settlement at some point in the future.
When the first round of lawsuits started early this year, I had a feeling that Eysium was going for a takeover of ChromaDex since that company seemed to have other problems not related to Elysium. From this summer, however, I began to think there will be two major players, Elysium and ChromaDex, with possibly others going Elysium’s route and buying NR that is not protected by a patent if that is possible. I’ve assumed the source has been from a company in China.
Unfortunately, there is incentive for both companies to not put the detailed results of their 120 and 140 person trials of NR/pterostilbine (Elysium) and just NR (ChromaDex) up on its websites any time soon. Eventually, the results of other human trials will come out but until then how effective NR is with blood pressure, blood sugar level, etc will remain unknown.
For anyone interested in the continuing NR (nicotinamide riboside = version of vitamin B3) saga:
Researchers from the University of Colorado along with ChromaDex, the erstwhile monopoly supplier of NR, now shifting to a retailer of NR, held a conference on the results of people taking 1000 mg of NR a day versus those taking a placebo but will not release the results to the public yet.
Elysium, with its six Nobel laureates on its science advisory board, found a new source of NR after ChromaDex blocked their supply (ChromaDex have sued Elysium for non-payment), and I assume it is from somewhere like China where the manufacturing patent for NR does not hold. Elysium has also filed a complaint against the existence of ChromaDex’s NR manufacturing patents.
The co-founder of Elysium, Leondard Guarente, an MIT longevity microbiologist, said recently that six more trials of their BASIS (NR with pterostilbine) are about to start testing health endpoints at more levels of each molecule. They also haven’t released the detailed data of their 120 person (ages 60 to 79) study that was completed last July.
So more trial results delays, but it looks promising that Elysium is setting up six more trials and also trials for other compounds. NR has already been shown to be helpful in improving heart failure in mice and Guarente is optimistic that Elysium / NR will “disrupt the neutraceutical industry and maybe have ripples that affect the drug industry”, and I’m guessing one major area will be heart health.
Leonard Guarente speaking for 15 minutes at MIT: